share_log

天茂集团(000627.SZ):控股子公司国华人寿1-6月累计原保险保费收入约为246亿元

Hubei Biocause Pharmaceutical (stock code: 000627.SZ): The cumulative original insurance premium income of its holding subsidiary China Best Life from January to June is about 24.6 billion yuan.

Gelonghui Finance ·  Jul 8 08:00

On July 8th, Gelunhui reported that Hubei Biocause Pharmaceutical (000627.SZ), a controlling subsidiary, has been implementing business development in accordance with the overall concept of 'firmly transforming and developing, highlighting value growth, comprehensively enhancing capabilities, and moving towards a mature insurance enterprise', deepening the value of business and continuously promoting the optimization of business structure. The cumulative original insurance premium income from January 1st, 2024 to June 30th, 2024 was approximately RMB 24,607.559 million.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment